Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risvutatug Rezetecan + Ivonescimab in Advanced Solid Tumors
NCT07602855Phase 2Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of risvutatug rezetecan in lung cancer, sponsored by GSK. Started Sep 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07602855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07602855.